PharmaCielo Ltd. · issuer-reported TSXV: PCLO / OTC Pink: PCLOF
Financing and liquidity
Status: NotRated · held. Rating, target, reference quote and upside are null. Evidence confidence is moderate for the dated May financing and December capital and maturity disclosures, and low for current liquidity, post-maturity debt, capitalization, operating economics and independently rendered venue status. Author holdings, relationships and conflicts are unknown.
PharmaCielo’s supportable initial case is a financing-and-liquidity review, not a current operating-results review. The readable issuer May disclosure, dated May 19, 2026 and published at that URL on May 22, reports that the company issued 11,145,999 shares at an effective C$0.08 to satisfy C$891,681.85 of semiannual interest on 11% secured debentures. It also reports that approximately C$2.5 million had been drawn from a C$3.0 million related-party bridge commitment. Those facts show reliance on share-settled interest and insider liquidity; they do not establish unrestricted cash, bridge availability after May or an exact current debt balance.
The May figures imply 83.33% bridge utilization and C$0.5 million of nominally undrawn commitment. Multiplying 11,145,999 shares by the rounded C$0.08 price gives C$891,679.92, C$1.93 below the stated interest amount. That difference confirms that the disclosed effective price is rounded; it does not establish principal or a fully diluted denominator.
The readable issuer December capital disclosure, dated December 30, 2025 and published at that URL on January 27, 2026, reports a C$20.026 million working-capital deficiency at September 2025 and C$15.43 million of current debentures. It also reports approximately C$4 million of subsequent repayments and describes the remaining secured debentures as maturing in June 2026. These dated figures do not establish current cash, the amount outstanding after the stated maturity, or whether any balance was repaid, amended, extended, converted, defaulted or restructured.
A defensible full underwrite still requires current audited financial statements and cash flow, an exact debenture and bridge schedule, post-August common shares, options and warrants, recurring export volumes and unit economics, sustainable working capital and reinvestment, independently confirmed security status, financing rights and a compatible dated quote. Current cash, post-maturity debt, post-August capital, export economics and valuation remain unresolved.
Evidence state: the current reviewed hold fingerprint is f3a1af25b98bbcbaaa9735691de32b315b783f9f4d8fd9e4fbe53f7a03a89be5. It records the evidence boundary; it does not create a rating or target.